Sold as Santyl. Every FDA application for this active ingredient.
As of Nov 14, 2026, FDA lists 1 application for Collagenase (sold as Santyl), first approved Jun 4, 1965, with 0 new uses approved and 0 published complete response letters.
| Prospective Evaluation of Recombinant Pbserum Plus® and Pbserum HA 2.0® in Aesthetic and Regenerative BioremodelingSkin Laxity, Localized Adiposity · Antony Barbosa Institute | Not applicable | Not yet recruiting | Nov 2, 2026 |
| Application of Autologous Adipose Stromal Vascular Fraction in the Treatment of Diminished Ovarian ReserveDiminished Ovarian Reserve (DOR) · Peking University Third Hospital | Not applicable | Not yet recruiting | Oct 28, 2026 |
| PREPUP: A Randomized Trial of Bonvadis® Versus Collagenase Ointment in Diabetic Foot UlcersDiabetic Foot Ulcers (DFUs) · Oneness Biotech Co., Ltd. | Not applicable | Not yet recruiting | Aug 21, 2026 |
| Autologous Fat Grafting for the Treatment of Chronic TendinopathyChronic Tendinopathy · Weill Medical College of Cornell University | Not applicable | Recruiting | Aug 6, 2026 |
| Collagenase Injection for Spasticity ManagementSpasticity · The University of Texas Health Science Center, Houston | Early phase 1 | Not yet recruiting | Jul 9, 2026 |
| Collagenase Injection for Contracture ManagementContracture · The University of Texas Health Science Center, Houston | Early phase 1 | Not yet recruiting | Jul 9, 2026 |
| Safety and Efficacy Study of Collagenase CNT201 Injection for Treatment of Dupuytren's ContractureDupuytren Contracture, Dupuytren Disease of Finger · CONNEXT | Phase 1 / Phase 2 | Recruiting | Jun 10, 2026 |
| Multi-Omics Insights Into Androgenetic AlopeciaAndrogenetic Alopecia (AGA) · The First Affiliated Hospital of Xinxiang Medical College | — | Recruiting | May 22, 2026 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Jun 4, 1965 | SantylBLA 101995 · New molecular entity | Smith And Nephew | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA